Skip to main content

Wave Life Sciences, Inc.

corporate_fare Company Profile

Wave Life Sciences, Inc.

WVE·NASDAQ·Life Sciences·CIK 0001631574

We are a clinical-stage biotechnology company focused on developing ribonucleic acid ("RNA") medicines, also known as oligonucleotides, or those targeting RNA, to improve human health. Our PRISM® RNA medicines platform integrates multiple approaches, chemistry innovations, and insights from human genetics to create scientific advancements for both rare and common disorders. Our platform includes RNA-targeting methods such as RNAi (SpiNA) and RNA editing (AIMers). Our pipeline includes programs for obesity (WVE-007), alpha-1 antitrypsin deficiency ("AATD") (WVE-006), and PNPLA3 I148M liver disease (WVE-008). We also have clinical programs for Duchenne muscular dystrophy ("DMD") and Huntington's disease ("HD"), along with several preclinical programs. We were founded over a decade ago to use chemistry innovation to adjust the pharmacological properties of oligonucleotides. Our chemistry modifications have been observed in clinical trials to enhance the potency, distribution, and durability of our molecules. Our chemistry allows us to use clinically proven conjugates, such as N-acetylgalactosamine ("GalNAc"), or free uptake for delivery to various cell and tissue types, rather than complex delivery vehicles like lipid nanoparticles and viruses. We hold intellectual property for our novel chemistry modifications. Our chemistry capabilities have also enabled new biological applications, including using adenosine deaminases acting on RNA ("ADAR") enzymes for messenger RNA ("mRNA") correction and upregulation, and selectively silencing a mutant allele.

Wave Life Sciences, Inc. (NASDAQ:WVE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for WVE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-27, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for WVE spans 10-Q, 8-K12B, 8-K, DEF 14A.

Recent high-impact activity:

  • Wave Q3 Loss Widens to $61.9M; Cash Falls to $431.0M With No ATM Sales
  • Wave Posts $61.9M Q3 Loss, Cash Runway to 3Q 2028, GSK Picks siRNA Candidate
  • FDA Backs Registrational Path for Wave's RNA Editing Drug in AATD
  • Wave Life Sciences Starts Phase 2a Trial of WVE-007 with Tirzepatide for Obesity
  • Wave Life Sciences finalizes Delaware redomiciliation, new parent company assumes control

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$42.73M
Net Income
-$204.38M
Diluted EPS
-$1.21
Op. Cash Flow
-$187.49M
Free Cash Flow
-$188.21M
Operating Income
-$215.38M
Cash & Equivalents
$602.07M
Debt / Equity
0.00×
Net Margin
-478.3%
Shares Outstanding
187.66M sh
Source: 10-K · filed 2026-04-30 · accession 0001193125-26-197330

Short Interest & Short Volume

6.76 days to cover

FINRA reported short interest of 20,649,846 shares in WVE as of the October 30, 2026 settlement, a 2.4% decrease from the prior period — about 6.8 days to cover at its recent average daily volume. On November 19, 2026, 49.7% of WVE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)20,649,846 shares as of October 30, 2026
Change vs prior period▼ 2.4%
Days to cover6.76 at avg daily volume of 3,056,842
Daily short volume (FINRA facilities)49.7% of 923,959 shares on November 19, 2026
5-day average short volume52.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for WVE, detected from its recent SEC filings.

ATM program

Shelf Registration Adopted for New Delaware Parent · ATM Program Prospectus Updated

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with W →
$2.65 -2.39% today
52-week range · as of 2026-10-27 $2.65 – $21.73
Market cap
$524.63M
Volume
669.9K (0.2× avg)
3-mo avg 2.8M
Live data · 2026-11-20 17:26 UTC · Market open

show_chartPrice Chart

Loading chart...

feed WVE - Latest Insights

WVE
Oct 27, 2026, 7:50 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.42
Real-time Price: $2.66 info
Change: -$0.765 (-22%) info
Market Cap: $524.629M info
WVE
Oct 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $2.66 info
Change: -$0.795 (-23%) info
Market Cap: $524.629M info
WVE
Oct 01, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.71
Real-time Price: $2.66 info
Change: -$1.06 (-28%) info
Market Cap: $524.629M info
WVE
Sep 23, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.50
Real-time Price: $2.66 info
Change: -$1.85 (-41%) info
Market Cap: $524.629M info
WVE
Aug 07, 2026, 4:52 PM EDT
Filing Type: 8-K12B
Importance Score:
7
Price at Filing: $6.14
Real-time Price: $2.66 info
Change: -$3.48 (-57%) info
Market Cap: $524.629M info
WVE
Jul 30, 2026, 7:50 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.38
Real-time Price: $2.66 info
Change: -$2.73 (-51%) info
Market Cap: $524.629M info
WVE
Jul 30, 2026, 7:38 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.51
Real-time Price: $2.66 info
Change: -$2.86 (-52%) info
Market Cap: $524.629M info
WVE
Jun 26, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.75
Real-time Price: $2.66 info
Change: -$3.10 (-54%) info
Market Cap: $524.629M info
WVE
May 18, 2026, 4:51 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.58
Real-time Price: $2.66 info
Change: -$3.93 (-60%) info
Market Cap: $524.629M info
WVE
May 18, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.62
Real-time Price: $2.66 info
Change: -$3.97 (-60%) info
Market Cap: $524.629M info
WVE
May 07, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $7.24
Real-time Price: $2.66 info
Change: -$4.59 (-63%) info
Market Cap: $524.629M info
WVE
May 01, 2026, 4:21 PM EDT
Filing Type: PRER14A
Importance Score:
8
Price at Filing: $7.32
Real-time Price: $2.66 info
Change: -$4.67 (-64%) info
Market Cap: $524.629M info
WVE
Apr 28, 2026, 7:50 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.13
Real-time Price: $2.66 info
Change: -$4.48 (-63%) info
Market Cap: $524.629M info
WVE
Apr 28, 2026, 7:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.27
Real-time Price: $2.66 info
Change: -$4.61 (-63%) info
Market Cap: $524.629M info
WVE
Apr 21, 2026, 5:05 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $7.40
Real-time Price: $2.66 info
Change: -$4.75 (-64%) info
Market Cap: $524.629M info
WVE
Apr 15, 2026, 4:10 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $7.65
Real-time Price: $2.66 info
Change: -$5.00 (-65%) info
Market Cap: $524.629M info
WVE
Mar 30, 2026, 8:32 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $6.63
Real-time Price: $2.66 info
Change: -$3.98 (-60%) info
Market Cap: $524.629M info
WVE
Mar 30, 2026, 8:30 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $6.63
Real-time Price: $2.66 info
Change: -$3.98 (-60%) info
Market Cap: $524.629M info
WVE
Mar 26, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.70
Real-time Price: $2.66 info
Change: -$6.05 (-69%) info
Market Cap: $524.629M info
WVE
Mar 05, 2026, 8:34 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $13.80
Real-time Price: $2.66 info
Change: -$11.15 (-81%) info
Market Cap: $524.629M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets